Metabolite Profiling of Meridianin C In Vivo of Rat by UHPLC/Q-TOF MS | Zendy

Guozhe Zhang | Zendy; Linxia Xiao | Zendy; Liang Qi | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Metabolite Profiling of Meridianin C In Vivo of Rat by UHPLC/Q-TOF MS

Author(s) -

Guozhe Zhang,

Linxia Xiao,

Liang Qi

Publication year - 2021

Publication title -

journal of analytical methods in chemistry

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.407

H-Index - 25

eISSN - 2090-8865

pISSN - 2090-8873

DOI - 10.1155/2021/1382421

Subject(s) - in vivo , chromatography , glucuronidation , chemistry , hydroxylation , metabolite , protein precipitation , mass spectrometry , solid phase extraction , metabolomics , biochemistry , biology , in vitro , enzyme , microbiology and biotechnology , microsome

Meridianin C (MC), as a marine alkaloid, is a potent protein kinase inhibitor which exhibits good anticancer activity. However, the in vivo metabolism of MC has not been described to date. In this study, an ultra-high performance liquid chromatography/quadrupole time-of-flight mass spectrometry (UHPLC/Q-TOF MS) method is employed to investigate the in vivo metabolites of MC in rats. Plasma, bile, urine, and feces are collected after a single oral dose of MC. Protein precipitation, solid phase extraction (SPE), and ultrasonic extraction methods are used to prepare samples. Based on the mass spectral fragmentation patterns, elution order, and retrieving literatures, a total of 13 metabolites of MC were detected and tentatively identified, utilizing MetaboLynx software. The metabolic pathways of MC in rats include N- or O-glucuronidation, O-sulfation, N-hydroxylation, dihydroxylation, and trihydroxylation. The relative content of the metabolites in each kinds of biological samples is also evaluated. This study will help to understand the in vivo properties of MC for the future usage.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research